BLI-489

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C13H10N3O4S.Na
Molecular Weight	327.291
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[O-]C(=O)C1=CS[C@H]2N1C(=O)\C2=C\C3=CN4CCOCC4=N3

InChI

InChIKey=RFSWVJXWZXQOSW-ZDFSRXSCSA-M

InChI=1S/C13H11N3O4S.Na/c17-11-8(12-16(11)9(6-21-12)13(18)19)3-7-4-15-1-2-20-5-10(15)14-7;/h3-4,6,12H,1-2,5H2,(H,18,19);/q;+1/p-1/b8-3-;/t12-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C13H10N3O4S
Molecular Weight	304.301
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800025895 | https://clinicaltrials.gov/ct2/show/NCT00854009

BLI 489 was developed by Wyeth as a 6-methylidene-penem β-lactamase inhibitor for the treatment of bacterial infections and urinary tract infections. BLI-489 has shown the promising clinical data, however, development of this drug, was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Relationship between β-lactamase production and resistance phenotype in Klebsiella pneumoniae strains.	2017-07-06	28591808
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.	2009-02	19001109

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:18:28 GMT 2025` Edited by `admin` on `Mon Mar 31 18:18:28 GMT 2025`
Record UNII	R56JYB8P8Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BLI 489

Preferred Name

English

BLI-489

Common Name

English

4-THIA-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 6-((5,6-DIHYDRO-8H-IMIDAZO(2,1-C)(1,4)OXAZIN-2-YL)METHYLENE)-7-OXO-, SODIUM SALT (1:1), (5R,6Z)-

Common Name

English

Code System Code Type Description

FDA UNII

R56JYB8P8Z

Created by admin on Mon Mar 31 18:18:28 GMT 2025 , Edited by admin on Mon Mar 31 18:18:28 GMT 2025

PRIMARY

PUBCHEM

23697683

Created by admin on Mon Mar 31 18:18:28 GMT 2025 , Edited by admin on Mon Mar 31 18:18:28 GMT 2025

PRIMARY

CAS

623564-40-9

Created by admin on Mon Mar 31 18:18:28 GMT 2025 , Edited by admin on Mon Mar 31 18:18:28 GMT 2025

PRIMARY

Related Record Type Details


					156B510BCG

BLI-489 FREE ACID

PARENT -> SALT/SOLVATE

Details

SMILES

InChI

DescriptionSources: https://adisinsight.springer.com/drugs/800025895 | https://clinicaltrials.gov/ct2/show/NCT00854009

Originator

Approval Year

PubMed

Sample Use Guides

Description
Sources: https://adisinsight.springer.com/drugs/800025895 | https://clinicaltrials.gov/ct2/show/NCT00854009